Upcoming Cancer Infection & Immunity
CANTO – CAR T-Cell Associated Neuropsychiatric Toxicity and Outcomes: a prospective longitudinal study of cognitive and psychiatric effects of CAR T-cell therapy and their predictors
About this grant
This summary is based on the grant title only — the full abstract was not available.
Research project funded by MRF at King's College London.
View the original record at the funder ↗
Researchers
Thomas Pollak (EPMC Awardee)
Related Research
Grants with similar aims, by meaning.
Understanding the mechanisms of immune effector cell associated neurotoxicity syndrome (ICANS) in patients receiving chimeric antigen receptor (CAR) T cell therapy for cancer
BCMA/CD19 targeting CAR T cell for AL Amyloid: Phase 1 trial assessing the treatment of AL Amyloid (relapsed/refractory to previous therapy) with CAR T cells
Chimeric antigen receptor (CAR) T cell therapy related cardiovascular outcomes
Chimeric antigen receptors T [CAR-T] cell therapy in immune mediated neurological disorders
An open-label, multi-centre, phase ib/ii study evaluating the safety and efficacy of auto1, a car t cell treatment targeting cd19, in adult patients with relapsed or refractory b cell acute lymphoblastic leukaemia
Original classification
Impact of Cancer and Cancer Care on Human Biology and Health 2025Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know